Technical datasheet
Description
The monoclonal antibody 80M2 recognizes the extracellular part of membrane-bound TNF-RII as well as the soluble form of TNF-RII which is generated by proteolytic cleavage of the extracellular domain. The soluble form can still bind TNF-alpha with high affinity and functions as a TNF-alpha antagonist. TNF-alpha is an important signaling protein in the immune system which can activate inflammatory responses, induce apoptosis, regulate cellular proliferation, and may even promote cancer progression. TNF-alpha can bind to two structurally distinct membrane receptors, TNF-RI and TNF-RII, which have both distinct and overlapping downstream signaling cascades. TNFRI is believed to be expressed on nearly all cell types, whereas TNFRII exhibits more restricted expression, being found on certain subpopulations of immune cells and several other cell types. A dominant role of TNF-RII has been shown in thymocyte activation by TNF-alpha, whereas induction of cytotoxicity and other functions are mediated largely by TNF-RI. TNF-RI is equally well activated by both the 17 kDa soluble and 26 kDa membrane-bound form, whereas TNF-RII is activated only by the membrane bound form of TNF-alpha. The antibody is a non-agonistic receptor modulating antibody. It enhances in vitro TNF alpha responses by increasing the affinity of the soluble form of TNF-alpha for TNF-RII.
Cross Reactivity
| Cross reactant |
Reactivity |
| Rat |
Yes |
Formulation
0.5 mg (100 µg/ml) 0.2 µm filtered antibody solution in PBS (exact concentration is indicated on the label)
Species
Mouse IgG1
Application
|
|
F
|
FC2
|
FS1,2,4,5
|
IA
|
IF2
|
IP3
|
P
|
W
|
|
Yes
|
|
●
|
●
|
●
|
●
|
●
|
|
|
|
No
|
|
|
|
|
|
|
|
|
|
N.D.
|
●
|
|
|
|
|
|
●
|
●
|
N.D.= Not Determined; F = Frozen sections; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IF = Immuno Fluorescence; IP = Immuno Precipitation; P = Paraffin sections; W = Western blot
Application IA has been tested by Hycult Biotech.
Application notes
FC: Antibody 80M2 was used to select HeLa cells expressing TNF-RII by FACS. As negative control mock transfected HeLa cells were used. (Ref.2)
FS: Antibody 80M2 functions as an allosteric modulator, which stabilizes the ligand-receptor complex. (Ref.1)
Use
For immunofluorescence and flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, dilutions have to be optimized in user’s experimental setting.
Aliases
Tumor necrosis factor receptor superfamily member 1B, CD120b, TNF-R2, p75, p80 TNF-alpha receptor
Negative control
Mock transfected HeLa cells
Positive control
HeLa cells transfected with TNF-RII
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
References
1. Grell, M et al; The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83: 793
2. Till, A et al; The Met 196 - Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha induced apoptosis by impaired NF-kB signalling and target gene expression. J Biol Chem 2005, 280: 5994
3. Scherubl C. et al; Colocalization of endogenous TNF with a functional intracellular splice form of human TNF receptor type 2. Journal of Inflammation 2005, 2: 7
4. Krippner, A et al; Single chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 2008, 180: 8176
5. Fairfax, B et al; A common haplotype of the TNF receptor 2 gene modulates endotoxin tolerance. J. Immonol 2011, 186: 3058
Precautions
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Also available
|
HM2022F
|
TNF-RII, Human, mAb 80M2, FITC
|
|
HM2023
|
TNF-RII, Human, mAb 80M2, biotinylated
|
|
HM2007
|
TNF-RII, Human, mAb MR2-1
|
|
HM2008
|
TNF-RII, Human, mAb MR2-1, biotinylated
|
|
HP9003
|
TNF-R II, Human, pAb
|
References
1. Grell, M et al; The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83: 793
2. Till, A et al; The Met 196 - Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha induced apoptosis by impaired NF-kB signalling and target gene expression. J Biol Chem 2005, 280: 5994
3. Scherubl C. et al; Colocalization of endogenous TNF with a functional intracellular splice form of human TNF receptor type 2. Journal of Inflammation 2005, 2: 7
4. Krippner, A et al; Single chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J Immunol 2008, 180: 8176
5. Fairfax, B et al; A common haplotype of the TNF receptor 2 gene modulates endotoxin tolerance. J. Immonol 2011, 186: 3058